Microsatellite Stability Colorectal Cancer(MSS CRC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The tumor cells are referred to as microsatellite stable (MSS) when the microsatellite DNA segments are unaltered (not mutated) in the colorectal cancer. Expression of mismatch repair genes and proteins is normal in colorectal cancers with MSS. Cancer cells with stable microsatellites can effectively fix mistakes in DNA mismatch repair. When the microsatellite DNA segments in cancer cells change (mutate), this shows a weakness in the tumor cells' ability to repair mismatch errors. 85% of CRCs (pMMR/MSS) are capable of performing mismatch repair or exhibiting microsatellite stability, compared to 15% of CRCs (dMMR/MSI) that do not. It is impossible to correct errors in microsatellites, a type of repetitive DNA, because mismatch repair genes (MMR) malfunction in MSI tumors, a subtype of colorectal cancer (CRC). Due to the development of immune checkpoint inhibitors, which has accelerated advancements in clinical practice, immunotherapy research has made significant strides for patients with mismatch repair deficient/microsatellite instability-high colorectal cancer. This advancement has not yet helped microsatellite stable colorectal cancer, which displays the signs of chromosomal instability.

Description

The tumor cells are referred to as microsatellite stable (MSS) when the microsatellite DNA segments are unaltered (not mutated) in the colorectal cancer. Expression of mismatch repair genes and proteins is normal in colorectal cancers with MSS. Cancer cells with stable microsatellites can effectively fix mistakes in DNA mismatch repair. When the microsatellite DNA segments in cancer cells change (mutate), this shows a weakness in the tumor cells' ability to repair mismatch errors. Microsatellite instability, also known as MSI-High, MSI-H, or mismatch repair deficiency, dMMR, is present in these colorectal cancers. It is possible that mutations or other genetic processes result in abnormally high levels of mismatch repair gene and protein expression in MSI tumors. It is known that different types of genomic instability promote the growth of colorectal cancer (CRC). 85% of CRC patients have chromosomal instability, which accounts for 15% of cases of MSI. Mismatch repair genes (MMR) malfunction in MSI tumors, a subset of colorectal cancer (CRC), making it impossible to correct mistakes in microsatellites, a type of repetitive DNA. The remaining 3% of MSI tumors (Lynch syndrome) have germline mutations in one of the MMR genes. 12% of MSI tumors are acquired, resulting from methylation-associated silencing of a gene that encodes a DNA MMR protein. Studies have shown that MSI tumors have a better stage-adjusted survival than microsatellite stable tumors, and they respond differently to 5FU-based adjuvant chemotherapy depending on this status, making the determination of the microsatellite stability status crucial for clinical purposes.

Microsatellite Stability Colorectal Cancer(MSS CRC)(Epidemiology)

85% of CRCs (pMMR/MSS) are capable of performing mismatch repair or exhibiting microsatellite stability, compared to 15% of CRCs (dMMR/MSI) that do not. It is impossible to correct errors in microsatellites, a type of repetitive DNA, because mismatch repair genes (MMR) malfunction in MSI tumors, a subtype of colorectal cancer (CRC). 12% of acquired MSI tumors are caused by methylation-associated silencing of a gene that codes for a DNA MMR protein, and the remaining 3% of MSI tumors (Lynch syndrome) have germline mutations in one of the MMR genes. Microsatellite stability status must be determined clinically because research has shown that MSI tumors have a better stage-adjusted survival than microsatellite stable tumors and that, depending on this status, they respond differently to 5FU-based adjuvant chemotherapy. Colorectal cancer (CRC) is the second most frequent cancer in both men and women. In the US, there are 140,250 new cases of large bowel cancer annually, of which 97,220 are colon cancers and the remaining 14,250 are rectal cancers. CRC accounts for 50,630 reported deaths annually, or 8% of all cancer-related deaths in the nation. The incidence of colorectal cancer (CRC) has decreased by about 2% to 4% annually over the past 15 years in the United States, but it is increasing among people under the age of 50 while decreasing among those over the age of 50.

Microsatellite Stability Colorectal Cancer(MSS CRC)-Current Market Size & Forecast Trends

The market for microsatellite stable colorectal cancer (MSS CRC) is expected to grow, with a projected increase from approximately USD 22.28 billion in 2024 to around USD 30.10 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.4% during this period. This growth is driven by the rising incidence of colorectal cancer and the ongoing development of treatment options, including chemotherapy and targeted therapies, particularly as immunotherapy has shown limited efficacy in MSS CRC cases. The overall colorectal cancer therapeutics market, which includes MSS CRC, is anticipated to expand from USD 12.79 billion in 2024 to about USD 19.95 billion by 2034, indicating a CAGR of 4.5%. As research continues to focus on improving treatment strategies and increasing awareness of colorectal cancer, the MSS CRC market is well-positioned for steady growth through 2035.

Due to the development of immune checkpoint inhibitors, which has accelerated advancements in clinical practice, immunotherapy research has made significant strides for patients with mismatch repair deficient/microsatellite instability-high colorectal cancer. This advancement has not yet helped microsatellite stable colorectal cancer, which displays the signs of chromosomal instability. The lack of discernible therapeutic benefits from immune checkpoint inhibitor therapy for patients with microsatellite stable colorectal cancer has been unexpected. Recently, immune checkpoint inhibitors have been combined with tyrosine kinase inhibitors and targeted therapies to see if there are any synergistic effects that could enhance antitumor activity in the tumor microenvironment and result in more notable clinical and radiologic responses. Multiple trials based on immune checkpoint inhibitors have been started as a result of immunotherapy's recent success, specifically anti-PD1 drugs, in treating metastatic CRC with MMR dysfunction. Additionally, it's critical to recognize Lynch syndrome patients in order to inform recommendations for prophylactic surgery and the frequency of CRC surveillance. Molecular tumor heterogeneity contributes to significant variability in clinical outcomes despite the same disease stage; therefore, it is important to understand the type of genomic instability pathway that the tumor harbors. TNM staging continues to be a key factor in determining patient prognosis and directing management in patients with CRC.

Report Highlights

Microsatellite Stability Colorectal Cancer (MSS CRC)- Current Market Trends

Microsatellite Stability Colorectal Cancer (MSS CRC)- Current & Forecasted Cases across the G8 Countries

Microsatellite Stability Colorectal Cancer (MSS CRC)- Market Opportunities and Sales Potential for Agents

Microsatellite Stability Colorectal Cancer (MSS CRC)- Patient-based Market Forecast to 2035

Microsatellite Stability Colorectal Cancer (MSS CRC)- Untapped Business Opportunities

Microsatellite Stability Colorectal Cancer (MSS CRC)- Product Positioning Vis-a-vis Competitors' Products

Microsatellite Stability Colorectal Cancer (MSS CRC)- KOLs Insight